These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17086220)

  • 1. [Treatment of hormone-resistant prostate cancer].
    Lilleby W; Hernes E; Waehre H; Raabe N; Fosså SD
    Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2798-801. PubMed ID: 17086220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing pattern of management for hormone-refractory, metastatic prostate cancer.
    James ND; Bloomfield D; Luscombe C
    Prostate Cancer Prostatic Dis; 2006; 9(3):221-9. PubMed ID: 16801939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
    Serrate C; Loriot Y; De La Motte Rouge T; Gross-Goupil M; Massard C; Escudier B; Bossi A; Fizazi K
    Ann Oncol; 2009 May; 20(5):965. PubMed ID: 19403938
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
    Okajima K; Yamashita Y; Onuki T; Fujinami K; Senga Y; Goto A; Jinza S; Asakura T
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1247-9. PubMed ID: 18633274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
    J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
    Olbert PJ; Hegele A; Kraeuter P; Heidenreich A; Hofmann R; Schrader AJ
    Anticancer Drugs; 2006 Sep; 17(8):993-6. PubMed ID: 16940810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic options for hormone-refractory prostate cancer].
    Miller K; Börgermann C; Thüroff J; Albers P; Wirth M
    Urologe A; 2006 May; 45(5):580, 582-5. PubMed ID: 16710677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
    Silvestris N; Leone B; Numico G; Lorusso V; De Lena M
    Oncology; 2005; 69(4):273-82. PubMed ID: 16282706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.